Chemical | 10 June 2021
Ascend boosts production capacity for long-chain polyamides
The multi-million dollar expansion will help the company meet growing demand for its new product line
The multi-million dollar expansion will help the company meet growing demand for its new product line
The green loan funds, procured by SKBM from the Export-Import Bank of Korea, were obtained under large-scale and favorable financial terms in which SK Innovation would be under a guarantee of obligation
The new Freeport MDI facility will replace Dow’s current North America capacity in La Porte, Texas, and will also be capable of supplying an additional 30 percent of product to Dow’s customers
The contract, which combines UK innovation and world-leading Japanese technology, will see Drax license MHI’s unique carbon capture solvent, KS-21, to capture CO2 at its power station near Selby, North Yorkshire
The total sale price of $800 million consists of $725 million cash at closing and an additional amount of up to $75 million to be paid based on performance of the rubber additives business post-closing through 2023
Company will work together with Stanford University scientists to scale up the synthesis and formulation, and further develop this innovative technology for organ selective delivery based on a non-animal-derived, synthetic degradable polymer
Together with the shares it previously acquired, PPG now controls 97.1% of Tikkurila’s issued and outstanding shares
Under the joint venture agreement, PolyMirae will offtake and sell all polypropylene produced by the facility to customers throughout Asia
With expertise in the fields of organic residues, soil amendments, agricultural biofertilizers and smart irrigation, SUEZ will use the CarbonFX torrefaction technology developed by Airex Energy for the global deployment of industrial-scale production plants that transform residual lignocellulosic biomass (bark, sawdust, waste wood, etc.) into a stable carbon with high technical and environmental added-value known as “biochar.”
Near to medium term growth would remain under pressure due to slow recovery in radiopharma business
Company has established strong levers of growth to deliver superior performance over the medium term.
The company has reported total income of Rs.361.65 crores during FY 2020-21
The company reported total income of Rs.396.85 crores during FY 2020-21
The company reported total income of Rs.446.76 crores during FY 2020-21
The company reported total income of Rs.1023.95 crores during FY 2020-21
The company posted net profit of Rs.6.85 crores for FY 2020-21
The company posted net profit of Rs.2939.23 crores for the 12 months period ended March 31, 2021
The study was conducted in patients with mild to moderate COVID-19
The company has posted net profit of Rs.143.94 crores during FY 2020-21
The company has posted net profit of Rs.248.90 crores for the 12 months period ended March 31, 2021 as against net profit of Rs.423.81 crores for the 12 months period ended March 31, 2020.
Subscribe To Our Newsletter & Stay Updated
